FIELD: medicine.
SUBSTANCE: recovered lymphocytes are incubated in the presence of an enzyme in an incubation medium, and then the cells are washed from the enzyme. They are coloured by monoclonal antibodies containing a fluorescent label to relevant surface cell receptor determinants and compared to a reference, wherein the cells are incubated in an enzyme-free medium or in the presence of proteolytic enzyme inhibitors. The lymphocyte receptor expression is determined by flow cytometry.
EFFECT: using the given method enables detecting the proteolysis sensitive receptors and assessing the activity of enzymes and their inhibitors qualitatively.
3 ex, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR MULTIPLEX ANALYSIS OF B CELLS FOR ASSESSING THE CELLULAR LINK OF THE IMMUNE SYSTEM OF CATTLE | 2020 |
|
RU2761468C1 |
STRAIN OF CULTIVATED HYBRID ANIMAL CELLS MUS MUSCULUS LINNAEUS EN-4E4 - PRODUCER OF MONOCLONAL ANTIBODIES AGAINST HUMAN ENDOGLIN (CD105) | 2015 |
|
RU2604192C1 |
CULTIVATED HYBRID ANIMAL CELLS OF MUS MUSCULUS L.-EN-4C9 - PRODUCER OF MONOCLONAL ANTIBODIES AGAINST ENDOGLIN (CD105) | 2015 |
|
RU2607029C1 |
METHOD OF NEUTRALISATION OF HEPATITIS C VIRUS, COMPLETELY HUMAN HOMOGENEOUS ANTIBODY AGAINST HEPATITIS C VIRUS (VERSIONS), COMPOSITION OF COMPLETELY HUMAN HOMOGENEOUS ANTIBODIES AGAINST HEPATITIS C VIRUS AND HYBRID MOUSE/HUMAN CELL LINE - PRODUCENT OF COMPLETELY HUMAN HOMOGENEOUS ANTIBODIES AGAINST HEPATITIS C VIRUS (VERSIONS) | 2013 |
|
RU2539770C1 |
MONOMOLECULAR CHIMERIC T-CELL RECEPTOR TO CANCER ANTIGEN CA125 | 2018 |
|
RU2747095C2 |
BTN2-SPECIFIC ANTIBODIES AND USE THEREOF | 2020 |
|
RU2821703C2 |
USING MONOCLONAL ANTIBODIES FOR IDENTIFYING YAMAGATA OR VICTORIAN INFLUENZA B VIRAL EVOLUTION LINE, HYBRIDOMA 4H7 STRAIN FOR PREPARING MONOCLONAL ANTIBODIES USED TO IDENTIFY INFLUENZA B VIRUSES IN YAMAGATA BRANCH, HYBRIDOMA B/4H1 STRAIN FOR PREPARING MONOCLONAL ANTIBODIES USED TO IDENTIFY INFLUENZA B VIRUSES IN VICTORIAN BRANCH | 2011 |
|
RU2491338C2 |
ANTIBODY AND CHEMOKINE CONSTRUCTS AND USES THEREOF IN IMMUNOLOGICAL DISORDERS | 2001 |
|
RU2252786C2 |
METHOD FOR ANGIOGENESIS INHIBITION WITH RECOMBINANT FORMS OF UROKINASE | 2012 |
|
RU2528249C2 |
METHOD FOR INTERFERON-GAMMA PRODUCING T-LYMPHOCYTE TEST IN CHRONIC LYMPHATIC LEUKAEMIA | 2012 |
|
RU2526797C2 |
Authors
Dates
2014-03-20—Published
2012-07-16—Filed